Amneal Pharmaceuticals (NYSE:AMRX) reported its Q1 earnings results on Friday, May 5, 2023 at 06:00 AM.
Here’s what investors need to know about the announcement.
Earnings
Amneal Pharmaceuticals beat estimated earnings by 20.0%, reporting an EPS of $0.12 versus an estimate of $0.1.
Revenue was up $59.91 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.02 which was followed by a 3.52% drop in the share price the next day.
Here’s a look at Amneal Pharmaceuticals’s past performance:
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | 0.21 | 0.18 | 0.20 | 0.13 |
| EPS Actual | 0.23 | 0.14 | 0.19 | 0.12 |
| Revenue Estimate | 579.91M | 564.15M | 536.34M | 503.97M |
| Revenue Actual | 609.76M | 545.56M | 559.36M | 497.63M |
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Guidance
Amneal Pharmaceuticals management provided guidance for FY 2023, expecting earnings between $0.4 and $0.5 per share.
To track all earnings releases for Amneal Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
